High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations by Maeng, Chi Hoon et al.
 
High-Throughput Genotyping in Metastatic Esophageal Squamous
Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF
Mutations
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Maeng, Chi Hoon, Jeeyun Lee, Paul van Hummelen, Se Hoon
Park, Emanuele Palescandolo, Jiryeon Jang, Ha Young Park, So
Young Kang, Laura MacConaill, Kyoung-Mee Kim, and Young-
Mog Shim. 2012. High-throughput genotyping in metastatic
esophageal squamous cell carcinoma identifies phosphoinositide-
3-kinase and BRAF mutations. PLoS ONE 7(8).
Published Version doi:10.1371/journal.pone.0041655
Accessed February 19, 2015 10:49:11 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436288
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAHigh-Throughput Genotyping in Metastatic Esophageal
Squamous Cell Carcinoma Identifies Phosphoinositide-3-
Kinase and BRAF Mutations
Chi Hoon Maeng
1, Jeeyun Lee
1*, Paul van Hummelen
2, Se Hoon Park
1, Emanuele Palescandolo
2,
Jiryeon Jang
1, Ha Young Park
3, So Young Kang
3, Laura MacConaill
2, Kyoung-Mee Kim
3, Young-
Mog Shim
4
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 2Center for Cancer
Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, 3Department of Pathology, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 4Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Korea
Abstract
Background: Given the high incidence of metastatic esophageal squamous cell carcinoma, especially in Asia, we screened
for the presence of somatic mutations using OncoMap platform with the aim of defining subsets of patients who may be
potential candidate for targeted therapy.
Methods and Materials: We analyzed 87 tissue specimens obtained from 80 patients who were pathologically confirmed
with esophageal squamous cell carcinoma and received 5-fluoropyrimidine/platinum-based chemotherapy. OncoMap 4.0,
a mass-spectrometry based assay, was used to interrogate 471 oncogenic mutations in 41 commonly mutated genes.
Tumor specimens were prepared from primary cancer sites in 70 patients and from metastatic sites in 17 patients. In order
to test the concordance between primary and metastatic sites from the patient for mutations, we analyzed 7 paired
(primary-metastatic) specimens. All specimens were formalin-fixed paraffin embedded tissues and tumor content was
.70%.
Results: In total, we have detected 20 hotspot mutations out of 80 patients screened. The most frequent mutation was
PIK3CA mutation (four E545K, five H1047R and one H1047L) (N=10, 11.5%) followed by MLH1 V384D (N=7, 8.0%), TP53
(R306, R175H and R273C) (N=3, 3.5%), BRAF V600E (N=1, 1.2%), CTNNB1 D32N (N=1, 1.2%), and EGFR P733L (N=1, 1.2%).
Distributions of somatic mutations were not different according to anatomic sites of esophageal cancer (cervical/upper,
mid, lower). In addition, there was no difference in frequency of mutations between primary-metastasis paired samples.
Conclusions: Our study led to the detection of potentially druggable mutations in esophageal SCC which may guide novel
therapies in small subsets of esophageal cancer patients.
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Introduction
Esophageal cancer is the sixth most common cause of cancer
worldwide and the incidence rates vary according to sex,
countries, and histological types [1]. While esophageal adenocar-
cinoma is more frequent in Western countries, squamous cell
carcinoma is the dominant histologic subtypes globally [1,2].
Esophageal cancer is a highly aggressive disease and the 5-year
survival rate is approximately 15% [3]. Approximately 50% of
patients show distant metastasis and half of the remaining patients
who initially present with locoregional disease eventually develop
distant metastases. In case of metastatic disease, median survival is
less than a year despite of palliative chemotherapy [3].
The role of chemotherapy in metastatic esophageal cancer has
not yet been documented through phase III trials and median
survival is less than 10 months despite conventional chemotherapy
[4,5]. Given the high incidence of metastatic esophageal squamous
cell carcinoma (SCC) in East Asia and the poor prognosis with
ineffectiveness of conventional chemotherapy, there is an urgent
need to find novel targeted agents to improve treatment outcomes.
PLoS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e41655Nowadays, there are somatic mutations known to be predictive of
drug sensitivity or drug resistance. We have adapted a high-
throughput genotyping platform to determine the mutation status
of a large panel of known cancer oncogenes to identify the subsets
of esophageal cancer patients who may potentially benefit from
targeted therapy [6,7]. The genotyping platform, termed Onco-
Map, employs mass spectrometric-based genotyping technology
(Sequenom) to identify 471 oncogenic mutations in 41 commonly
mutated genes (Table S1). In this study, we screened for somatic
mutations using high-throughput technology in an attempt to
identify potential target populations for molecularly targeted
agents in esophageal SCC.
Results
In this study, we examined 87 esophageal squamous cell
carcinoma samples from which 70 were from primary tumor sites
and 17 from metastatic sites (80 patients in total). We included 7
pairs of primary-metastatic esophageal SCC. All patients had
histologically confirmed squamous cell carcinoma and all patients
received fluoropyrimidine/platinum chemotherapy between Jan-
uary 2008 and January 2010. The baseline characteristics are
summarized in Table 1. Among the 87 FFPE samples tested, 23
mutations were identified and validated. The 11 mutations that
were identified involved 6 genes (Table 2). Of 11 mutations, 4
mutations were located in PIK3CA, thus the most frequently
observed somatic mutations in esophageal SCC. All 4 hotspots in
PIK3CA, E545K, E542K, H1047R, H1047L, are known to be
oncogenic in various tumor types [8–11]. There was no significant
association between anatomic location and PIK3CA mutations.
Of the 9 cases with PIK3CA mutations, 4 (44.4%) patients had
mid-esophagus, one (11.1%) had upper-esophagus and 4 (44.4%)
had distal esophageal cancer. Next, we examined the impact of
PIK3CA mutations on treatment outcome after fluoropyrimidine/
cisplatin chemotherapy. Overall, there was no significant differ-
ence in overall survival between the two groups (PIK3CA
mutation (+)v s( 2), 8.0 and 4.4 months, respectively, P=0.842)
(Figure 1). TP53 mutations were observed in 3 cases (3.5%). In
addition, we found one BRAF V600E (1 of 80 patients, 1.2%) and
one CTNNB1 D32N (1 of 80 patients, 1.2%) and one EGFR
P733L (1 of 80 patients, 1.2%).
We included 7 pairs of primary-metastatic tumor specimens in
order to evaluate the concordance rate of somatic mutations
between primary and metastatic tumors. We observed 100%
concordance rate of mutations between primary-metastatic pairs
(Table 3). There was one case (MLH1 V384D) that harbored
mutation in both of primary and metastatic tumor tissues. The
remainders showed no mutations from primary or metastatic sites.
Discussion
In this study, we performed high-throughput screening in
metastatic, unresectable esophageal SCC with the aim of
identifying mutations for molecularly targeted agents. There are
very limited options to treat metastatic esophageal SCC and
clinical trials incorporating novel agents are severely limited.
Overall, 20 (25%) of 80 patients screened using OncoMap had
somatic mutations. We identified that 11% of metastatic
esophageal SCC had PIK3CA mutations in exon 9 (E542K,
E545K) and exon 20 (H1047R, L) and that 1% of the patients
harbored BRAF V600E mutations.
There are scarce reports on PIK3CA mutations in esophageal
SCC. There is one study which directly sequenced tumor DNA
isolated from FFPE and identified 4 of 35 (11.8%) esophageal SCC
to have PIK3CA mutation [12]. Based on these results,
identification of PIK3CA mutation may define a subset of patients
who may be potential candidates for PIK3CA inhibitor treatment
[13]. In addition, mTOR inhibitors and AKT inhibitors are
currently under the investigations to target subsets of tumors with
aberrant PIK3 pathway [14,15]. A recent preclinical study had
demonstrated that LY294002, a PI3K inhibitor, reduced the
proliferation of the esophageal cancer cell line in vitro [16].
There was one patient (1 of 80) who harbored an oncogenic
BRAFV600E mutation in our series. To the best of our
knowledge, this is the first report on the BRAF mutation in
esophageal SCC. BRAF has taken center stage due to the
discovery that it is mutated in prevailing human cancers, including
60% of malignant melanomas and 5%–15% of colon, ovarian,
and thyroid carcinomas [17]. The most common mutation is
V600E, which dramatically enhances BRAF enzyme activity, and
thus induces tumorous transformation. Recently, vemurafenib,
a potent inhibitor of mutated BRAF [18], has demonstrated
a survival benefit in metastatic melanoma with BRAFV600E
mutation [19]. Although preclinical study on efficacy of BRAF
inhibitors is yet to be tested in esophageal SCC, prospective
screening for the presence of BRAF mutation should be actively
considered in esophageal SCC given the lack of treatment options
for these patients.
TP53 is a tumor suppressor gene that encodes protein
mediating cell apoptosis. Loss-of-function mutation of TP53 is
one of the most common features of human cancers [20]. In
COSMIC database published by Sanger institute, TP53 mutation
is the most common one among esophageal SCC (50%). Other
investigators have reported the frequency of TP53 mutation in the
range from 35% to 80% [20,21]. However, the frequency of TP53
mutation was lower (3.4%) in our series when compared to those
reported in previous studies. The lower rate of TP53 mutations in
this study is likely due to the fact that TP53 was genotyped at only
a 7 loci, rather than sequenced, and thus OncoMap is likely to
miss many such events. This is the first report of assessing
esophageal cancers from an Asian population and therefore there
is no independent validation series available. The proportion of
analyzed specimens from lower thirds portion of esophagus in our
report is 32.5%. As revious report, the incidence of esophageal
squamous cell carcinoma is thought to be approximately 50% [3],
the relatively fewer portion of specimen numbers could lead the
bias lowering mutation detection rates those are frequently found
in lower thirds esophagus. As mentioned above, the rate of TP53
mutations were reported exceptionally lower that previous data
such as COSMIC database. While the only detected muation in
lower third portion of esophagus is TP53 in the results from
COSMIC Database, we reported three detected TP 53 mutations
located in upper and middle thirds, suggesting omission of TP53
mutation detection possilby located in distal esophagus.
OncoMap platform, which we used for mutation screening, is
a reasonable substitute for direct sequencing method, not only in
fresh/frozen tissues but informalin-fixed paraffin-embedded spec-
imen (FFPE) [7]. The sensitivity and specificity of OncoMap is
approximately 89.3% and 99.4%, respectively when FFPE tissue is
used and those are comparable with the result from OncoMap
analysis using fresh frozen tissue [7]. One of the most remarkable
advantages of OncoMap is that it enables us to screen hundreds of
hotspot mutations using FFPE at reasonable cost [7]. In addition,
whole genome sequencing using fresh frozen tissues may not
always be feasible in metastatic solid tumor patients considering
poor medical condition and accessibility of tumor biopsy. Hence,
until whole genome sequencing or whole exome sequencing is
robustly confirmed in FFPE, clinicians have to utilize a reliable
way to screen for druggable hotspot mutations. OncoMap has
Somatic Mutations in Squamous Esophageal Cancer
PLoS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e41655Table 1. Baseline characteristics of patients.
N=80 % of Total Case
Sex Male 75 93.7
Female 5 6.3
Age (year) 43–74 (Median: 63)
Tissue Specimen Primary 70 80.4
Metastatic 17 19.6
Both 7 8.0
Metastatic Site Lymph node 9 50.6
Lung 2 11.7
Liver 2 11.7
Larynx 1 6.5
Small intestine 1 6.5
T/L spine 1 6.5
Femur 1 6.5
Differentiation Well 3 3.4
Moderate 38 43.7
Poor 8 9.2
Others 38 43.7
Anatomic sites Upper third 7 8.7
Middle third 37 46.3
Lower third 26 32.5
Upper to middle 2 2.5
Mid to lower 8 10
Primary resection Done 51 63.7
Not done 29 36.3
Chemotherapy Palliative (fluoropyrimidine/platinum-based chemotherapy) 78
Others 2
doi:10.1371/journal.pone.0041655.t001
Table 2. Frequency of somatic mutations in esophageal
squamous cell carcinoma.
Gene Amino acid Primary site Metastatic site %
{{
(n=70) (N=17)
{
PIK3CA E545K 2 0 11.5
E542K 2 0
H1047R 4 1
H1047L 1 0
MLH1 V384D 5 2 8.0
TP53 R306 1 0 3.5
R175H 1 0
R273C 1 0
BRAF V600E 1 0 1.2
CTNNB1 D32N 1 0 1.2
EGFR P733L 1 0 1.2
TOTAL 20 3 26.6
{7 cases were pairs of primary and metastatic organ.
{{Percentage of total number of patients (N=80).
doi:10.1371/journal.pone.0041655.t002
Figure 1. Overall survival according to PIK3CA mutation status.
doi:10.1371/journal.pone.0041655.g001
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from FFPE to screen for somatic mutations in multiple solid tumor
types [7,22,23].
The paradigm of cancer treatment is rapidly changing from
disease-specific type to target-specific approach such as testing the
efficacy of BRAF inhibitors in BRAF mutant solid tumors
regardless of primary sites. Using FFPEs, we successfully screened
80 metastatic esophageal SCC and have identified PIK3CA
mutation (11.5%) and BRAF mutation (1.2%) as potential targets
for further therapeutic development. Although the PIK3CA
mutation itself did not affect patients’ survival, effective targeting
the mutations can be associated with survival benefit. Based on this
study, we plan to propose clinical trials with PI3K inhibitors and/
or BRAF inhibitors.
Methods
Patients
We analyzed total 87 tissue specimens obtained from 80 patients
who had pathologically confirmed squamous SCC and treated in
Samsung Medical Center, Korea from January 2008 to December
2010. All patients had recurrent or metastatic disease and had
received 5-fluoropyrimidine/platinum-based chemotherapy. Of
the 87 tumor tissue specimens analyzed, 70 specimens were from
primary sites and 17 specimens were from metastatic sites. All
primary tumor and metastatic tumor samples were obtained from
formalin-fixed paraffin-embedded tumor specimens based on 80%
cutoff for tumor sample purity from a single institute. The quality
of all DNA samples was ensured by independent quantification
and quantitative PCR. The study was conducted after the
approval from the Samsung Medical Center Institutional Review
Board (SMC IRB). The primary tumor samples were all collected
from Samsung Medical Center. The study was approved by the
SMC IRB for informed consent waiver using archival tissues with
retrospective clinical data and all data was de-identified.
Selections of Oncogene Mutations and Genotyping
Our current OncoMap v4 interrogates 471 mutations in 41
genes that are relevant for cancer (Table S1). We selected various
known oncogenes and tumor suppressor genes based on previous
published literatures [6,7]. OncoMap v4 what we used for
genotyping analysis here is an expansion of Oncomap v1
previously mentioned by Macconaill et al [7]. We selected the
candidate somatic mutations in OncoMap v4 based on literature
reviews and frequently detected mutations reported in the
COSMIC Database. Genomic DNA was quantified using
Quant-iT
TM PicoGreenH dsDNAAssay Kit (Invitrogen) per
manufacturer’s protocol. 250 ng DNA was used for a mutation
analysis using Oncomap mass spectrometric genotyping based on
the Sequenom MassARRAYH technology and (Sequenom Inc,
San Diego, CA) performed as previously described high-through-
put oncogene mutation profiling in human cancer with some
modifications [6,7]. 100 ng of tumor-derived genomic DNA was
subjected to whole genome amplification (WGA). Next, up to 18-
multiplexed PCR was performed on tumor genomic DNA to
amplify regions harboring loci of interest. After denaturation, PCR
products were incubated with the probes that anneal immediately
adjacent to the query nucleotide and mass spectrometric
genotyping using iPLEX chemistries was performed (Sequenom
Inc, San Diego, CA) extending the probes with 1 base in the
presence of chain-terminating di-deoxynucleotides that generate
allele-specific DNA products. The extension products were spotted
onto a specially designed chip and analyzed by MALDI-TOF
mass spectrometry to determine the mutation status based on the
difference in mass of the mutant and wild type base.
Next, an automated mutation calling algorithm was performed
to identify candidate mutations. Putative mutations were further
filtered by a manual review and selected for validation using multi-
base homogenous Mass-Extend (hME) chemistry with a maximum
pooling of 6 assays on the remaining 150 ng DNA of each sample.
Primers and probes used for hME validation were designed using
the Sequenom MassARRAYH Assay Design 4.0 software, applying
default multi-base extension parameters.
Only mutations found in iPLEX and confirmed by hME were
considered as ‘validated mutations’. iPLEX candidate mutations
that were not confirmed by hME were considered as invalidated
and were not reported. Examples of all detected mutations were
confirmed by standard, bidirectional Sanger sequencing.
Supporting Information
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